Characterization of brain metastases using high-resolution magic angle spinning MRS

NMR in Biomedicine

Volumn 21, Issue 2, 2008, Pages 175-185

  Sjøbakk, Torill E ^a   Johansen, Roar ^a   Bathen, Tone F ^a   Sonnewald, Ursula ^a   Juul, Roar ^b   Torp, Sverre H ^a,b   Lundgren, Steinar ^a,b   Gribbestad, Ingrid S ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cancer; Carcinoma; Ex vivo MRS; Metabolite; Multivariate analysis; Predictive factor; Survival; Tumor

Indexed keywords

BRAIN; DIAGNOSIS; ENZYMES; LEAST SQUARES APPROXIMATIONS; METABOLITES; ONCOLOGY; PRINCIPAL COMPONENT ANALYSIS; REGRESSION ANALYSIS; TUMORS;

METASTASIS CLASSIFICATION; PARTIAL LEAST SQUARE REGRESSION ANALYSIS; PREDICTIVE FACTOR;

MAGNETIC RESONANCE SPECTROSCOPY;

ADULT; AGED; ARTICLE; BRAIN BIOPSY; BRAIN METASTASIS; CANCER CLASSIFICATION; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CORRELATION ANALYSIS; DEATH; DIAGNOSTIC VALUE; FEMALE; HIGH RESOLUTION MAGIC ANGLE SPINNING NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTIVARIATE ANALYSIS; NEOPLASM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTIAL LEAST SQUARES REGRESSION; POSTOPERATIVE PERIOD; PREDICTION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT PLANNING;

ADULT; AGED; BRAIN NEOPLASMS; CLUSTER ANALYSIS; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PRINCIPAL COMPONENT ANALYSIS; SIGNAL PROCESSING, COMPUTER-ASSISTED; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 40449121255     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1180     Document Type: Article

References (42)

1. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J. Neurooncol. 2005; 75: 5-14.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J. Clin. 2005; 55: 10-30.
3. Sawaya R, Bindal RK, Lang FF, Abi-Said D. Metastatic brain tumors. In Brain Tumors: An Encyclopedic Approach, Kaye AH, Laws ER Jr (eds). Harcourt Publishers Limited: London, 2001; 999-1026.
4. Sheehan J, Niranjan A, Flickinger JC, Kondziolka D, Lunsford LD. The expanding role of neurosurgeons in the management of brain metastases. Surg. Neurol. 2004; 62: 32-40.
5. Larson DA, Rubenstein JL, McDermott MW. Treatment of metastatic cancer. In Cancer: Principles and Practice of Oncology, DeVita VT Jr, Hellman S, Rosenberg SA (eds). Lippincott Williams and Wilkins: Philadelphia, 2005; 2323-2336.
6. Giordana MT, Cordera S, Boghi A. Cerebral metastases as first symptom of cancer: a clinico-pathologic study. J. Neurooncol. 2000; 50: 265-273.
7. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol. 2004; 22: 2865-2872.
8. Gaspar LE, Scott C, Murray K, Curran W. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 2000; 47: 1001-1006.
9. Salvati M, Cervoni L, Raco A. Single brain metastases from unknown primary malignancies in CT-era. J. Neurooncol. 1995; 23: 75-80.
10. Kaal EC, Niel CG, Vecht CJ. Therapeutic management of brain metastasis. Lancet Neurol. 2005; 4: 289-298.
11. Tosoni A, Ermani M, Brandes AA. The pathogenesis and treatment of brain metastases: a comprehensive review. Crit Rev. Oncol. Hematol. 2004; 52: 199-215.
12. Patchell RA. The management of brain metastases. Cancer Treat Rev. 2003; 29: 533-540.
13. Cheng LL, Anthony DC, Comite AR, Black PM, Tzika AA, Gonzalez RG. Quantification of microheterogeneity in glioblastoma multiforme with ex vivo high-resolution magic-angle spinning (HRMAS) proton magnetic resonance spectroscopy. Neuro. -oncol. 2000; 2: 87-95.
14. Cheng LL, Chang IW, Louis DN, Gonzalez RG. Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res. 1998; 58: 1825-1832.
15. 1H NMR spectroscopy. Ophthalmic Res. 2006; 38: 105-114.
16. Sitter B, Bathen T, Hagen B, Arentz C, Skjeldestad FE, Gribbestad IS. Cervical cancer tissue characterized by high-resolution magic angle spinning MR spectroscopy. MAGMA 2004; 16: 174-181.
17. 1H HR-MAS spectroscopy of intact biopsy samples in vitro. MAGMA 1999; 8: 121-128.
18. Sitter B, Sonnewald U, Spraul M, Fjøsne HE, Gribbestad IS. High-resolution magic angle spinning MRS of breast cancer tissue. NMR in Biomed. 2002; 15: 327-337.
19. 1H MRS study of human high grade gliomas. NMR Biomed. 2004; 17: 191-205.
20. Bathen TF, Jensen LR, Sitter B, Fjosne HE, Halgunset J, Axelson DE, Gribbestad IS, Lundgren S. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res. Treat. 2006; [Epub ahead of print]. DOI: 10.1007/ s10549-006-9400-z.
21. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J. Magn. Reson. Imaging 2002; 16: 451-463.
22. 1H MR spectra of a pediatric posterior fossa lesion. Int. J. Mol. Med. 2005; 16: 301-307.
23. 1H MR spectra. Int. J. Mol. Med. 2006; 18: 859-869.
24. Tzika AA, Cheng LL, Goumnerova L, Madsen JR, Zurakowski D, Astrakas LG, Zarifi MK, Scott RM, Anthony DC, Gonzalez RG, Black PM. Biochemical characterization of pediatric brain tumors by using in vivo and ex vivo magnetic resonance spectroscopy. J. Neurosurg. 2002; 96: 1023-1031.
25. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat. Rev. Cancer 2004; 4: 551-561.
26. Holmes E, Tsang TM, Tabrizi SJ. The application of NMR-based metabonomics in neurological disorders. NeuroRx 2006; 3: 358-372.
27. 1H magnetic resonance spectroscopy reveal significantly altered neuronal metabolite profiles in CLN1 but not in CLN3. J. Neurosci. Res. 2004; 77: 762-769.
28. 1H NMR spectroscopic characterization of perchloric acid extracts from breast carcinomas and non-involved breast tissue. NMR Biomed. 1994; 7: 181-194.
29. 1H magnetic resonance spectroscopy of brain metastases at 1.5T and 3T. Acta Radiol. 2006; 47: 501-508.
30. Esbensen K, Midtgaard T, Schonkopf S. Multivariate Analysis - In Practice. Camo AS: Trondheim, 1994; 1-361.
31. 1H/NMR spectroscopy study. Anticancer Res. 1994; 14: 793-798.
32. 1H MR spectroscopy of brain tumours and masses. NMR Biomed. 2003; 16: 123-131.
33. Graves EE, Nelson SJ, Vigneron DB, Verhey L, McDermott M, Larson D, Chang S, Prados MD, Dillon WP. Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am. J. Neuroradiol. 2001; 22: 613-624.
34. 1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed. 1994; 7: 149-155.
35. 1H MRSI. NMR Biomed. 1999; 12: 123-138.
36. Graves EE, Nelson SJ, Vigneron DB, Chin C, Verhey L, McDermott M, Larson D, Sneed PK, Chang S, Prados MD, Lamborn K, Dillon WP. A preliminary study of the prognostic value of proton magnetic resonance spectroscopic imaging in gamma knife radiosurgery of recurrent malignant gliomas. Neurosurgery 2000; 46: 319-326.
37. Kuznetsov YE, Caramanos Z, Antel SB, Preul MC, Leblanc R, Villemure JG, Pokrupa R, Olivier A, Sadikot A, Arnold DL. Proton magnetic resonance spectroscopic imaging can predict length of survival in patients with supratentorial gliomas. Neurosurgery 2003; 53: 565-574.
38. 1H NMR visible lipids in the life and death of cells. Trends Biochem. Sci. 2000; 25: 357-362.
39. 1H nuclear magnetic resonance correspond to lipid droplets. Cancer Res. 1997; 57: 407-414.
40. 1H-magnetic resonance spectroscopy: correlation with histopathology and immunohistochemistty. Neuroradiology 2006; 48: 312-318.
41. Mountford CE, Somorjai RL, Malycha P, Gluch L, Lean C, Russell P, Barraclough B, Gillett D, Himmelreich U, Dolenko B, Nikulin AE, Smith IC. Diagnosis and prognosis of breast cancer by magnetic resonance spectroscopy of fine-needle aspirates analysed using a statistical classification strategy. Br. J. Surg. 2001; 88: 1234-1240.
42. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 2006; 19: 30-40.